Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors put CHF18mm into Glycart Biotechnology

Executive Summary

Glycart Biotechnology AG, a private biotech developing therapeutic antibodies against cancer and autoimmune diseases, closed a CHF18mm ($13.6mm) Series A financing to lead investors Global Life Science Ventures and Gilde Investment Management, plus DVC Deutsche Venture Capital, ABN Amro, Quester Capital, BioMedinvest and returning investor Novartis Venture Fund.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies